Back to School: How biopharma can reboot drug development. Access exclusive analysis here

QLT beats Street, raises Visudyne guidance

QLT (TSE:QLT; QLTI) posted third quarter EPS of $0.25, beating the Street estimate

Read the full 136 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE